Common Stocks - 97.1%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 12.6%
|
|||
Biotechnology - 12.6%
|
|||
Allakos, Inc. (a)
|
27,700
|
2,170,295
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
21,571
|
3,964,750
|
|
Amicus Therapeutics, Inc. (a)
|
295,700
|
3,166,947
|
|
Argenx SE (a)
|
17,400
|
4,874,719
|
|
Argenx SE ADR (a)
|
11,000
|
3,071,310
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
51,300
|
7,029,126
|
|
Blueprint Medicines Corp. (a)
|
79,000
|
7,599,800
|
|
Celldex Therapeutics, Inc. (a)
|
73,400
|
2,796,540
|
|
Cullinan Oncology, Inc.
|
88,100
|
1,585,800
|
|
Galapagos NV sponsored ADR (a)(b)
|
36,900
|
1,792,602
|
|
Generation Bio Co. (a)(b)
|
44,576
|
765,370
|
|
Horizon Therapeutics PLC (a)
|
134,500
|
13,955,720
|
|
Innovent Biologics, Inc. (a)(c)
|
279,500
|
2,485,679
|
|
Intellia Therapeutics, Inc. (a)
|
15,400
|
1,771,154
|
|
Kalvista Pharmaceuticals, Inc. (a)
|
99,000
|
1,435,500
|
|
Leap Therapeutics, Inc. warrants 1/31/26 (a)
|
606,000
|
784,812
|
|
Protagonist Therapeutics, Inc. (a)
|
73,900
|
2,484,518
|
|
PTC Therapeutics, Inc. (a)
|
181,600
|
6,748,256
|
|
Sarepta Therapeutics, Inc. (a)
|
44,300
|
3,579,883
|
|
Springworks Therapeutics, Inc. (a)
|
44,300
|
3,182,955
|
|
Synlogic, Inc. (a)
|
520,800
|
1,296,792
|
|
TG Therapeutics, Inc. (a)
|
41,900
|
636,880
|
|
uniQure B.V. (a)
|
170,500
|
4,748,425
|
|
Vertex Pharmaceuticals, Inc. (a)
|
70,300
|
13,141,882
|
|
Xencor, Inc. (a)
|
49,568
|
1,795,353
|
|
XOMA Corp. (a)(b)
|
53,300
|
1,093,183
|
|
Zai Lab Ltd. ADR (a)
|
41,800
|
2,894,650
|
|
100,852,901
|
|||
Food & Staples Retailing - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (a)(d)
|
3,333
|
5,766
|
|
Health Care Equipment & Supplies - 1.9%
|
|||
Health Care Equipment - 1.9%
|
|||
Angelalign Technology, Inc. (c)
|
400
|
18,138
|
|
Boston Scientific Corp. (a)
|
402,300
|
15,315,561
|
|
15,333,699
|
|||
Health Care Providers & Services - 0.4%
|
|||
Health Care Services - 0.4%
|
|||
Guardant Health, Inc. (a)
|
25,500
|
2,680,560
|
|
Life Sciences Tools & Services - 3.5%
|
|||
Life Sciences Tools & Services - 3.5%
|
|||
23andMe Holding Co. Class B
|
396,605
|
3,097,088
|
|
Maravai LifeSciences Holdings, Inc.
|
386,500
|
17,755,810
|
|
Sartorius Stedim Biotech
|
11,700
|
6,918,441
|
|
27,771,339
|
|||
Pharmaceuticals - 78.7%
|
|||
Pharmaceuticals - 78.7%
|
|||
Arvinas Holding Co. LLC (a)
|
55,600
|
4,203,916
|
|
AstraZeneca PLC sponsored ADR
|
1,689,600
|
92,640,768
|
|
Atea Pharmaceuticals, Inc.
|
5,867
|
47,464
|
|
Axsome Therapeutics, Inc. (a)(b)
|
43,400
|
1,499,036
|
|
Bausch Health Cos., Inc. (Canada) (a)
|
67,800
|
1,609,218
|
|
Bristol-Myers Squibb Co.
|
1,125,580
|
60,364,855
|
|
Catalent, Inc. (a)
|
45,800
|
5,892,628
|
|
Elanco Animal Health, Inc. (a)
|
155,400
|
4,466,196
|
|
Eli Lilly & Co.
|
441,961
|
109,624,006
|
|
Harmony Biosciences Holdings, Inc. (a)(b)
|
73,077
|
2,491,195
|
|
Intra-Cellular Therapies, Inc. (a)
|
107,000
|
4,331,360
|
|
Johnson & Johnson
|
223,950
|
34,920,524
|
|
Merck & Co., Inc.
|
490,136
|
36,716,088
|
|
Nektar Therapeutics (a)(b)
|
368,233
|
4,146,304
|
|
NGM Biopharmaceuticals, Inc. (a)
|
108,600
|
1,956,972
|
|
Novartis AG sponsored ADR
|
344,796
|
27,480,241
|
|
Perrigo Co. PLC
|
73,800
|
2,709,198
|
|
Pliant Therapeutics, Inc. (a)
|
1,200
|
17,016
|
|
Reata Pharmaceuticals, Inc. (a)(b)
|
64,600
|
5,529,760
|
|
Roche Holding AG (participation certificate)
|
159,216
|
62,159,574
|
|
Royalty Pharma PLC
|
668,900
|
26,602,153
|
|
Sanofi SA sponsored ADR
|
1,498,922
|
71,303,720
|
|
UCB SA
|
261,200
|
28,479,256
|
|
Zoetis, Inc. Class A
|
181,200
|
40,233,648
|
|
Zogenix, Inc. (a)(b)
|
800
|
9,000
|
|
629,434,096
|
|||
TOTAL COMMON STOCKS
(Cost $560,851,928)
|
776,078,361
|
||
Convertible Preferred Stocks - 0.4%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 0.2%
|
|||
Biotechnology - 0.2%
|
|||
ValenzaBio, Inc. Series A (d)(e)
|
224,708
|
1,999,998
|
|
Diversified Financial Services - 0.2%
|
|||
Other Diversified Financial Services - 0.2%
|
|||
Paragon Biosciences Emalex Capital, Inc. Series C (d)(e)
|
158,879
|
1,342,528
|
|
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Castle Creek Pharmaceutical Holdings, Inc. Series C (a)(d)(e)
|
200
|
101,922
|
|
Software - 0.0%
|
|||
Systems Software - 0.0%
|
|||
Evozyne LLC Series A (d)(e)
|
5,900
|
132,573
|
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $3,914,946)
|
3,577,021
|
||
Convertible Bonds - 0.0%
|
|||
Principal
Amount (f)
|
Value ($)
|
||
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Castle Creek Pharmaceutical Holdings, Inc. 0.13% (d)(e)(g)
(Cost $14,700)
|
14,700
|
14,700
|
|
Money Market Funds - 1.8%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 0.06% (h)
|
9,119,827
|
9,121,651
|
|
Fidelity Securities Lending Cash Central Fund 0.07% (h)(i)
|
5,420,666
|
5,421,208
|
|
TOTAL MONEY MARKET FUNDS
(Cost $14,542,859)
|
14,542,859
|
||
TOTAL INVESTMENT IN SECURITIES - 99.3%
(Cost $579,324,433)
|
794,212,941
|
NET OTHER ASSETS (LIABILITIES) - 0.7%
|
5,335,699
|
NET ASSETS - 100.0%
|
799,548,640
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $2,503,817 or 0.3% of net assets.
|
(d)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $3,597,487 or 0.4% of net assets.
|
(e)
|
Level 3 security
|
(f)
|
Amount is stated in United States dollars unless otherwise noted.
|
(g)
|
Security is perpetual in nature with no stated maturity date.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Castle Creek Pharmaceutical Holdings, Inc. Series C
|
12/09/19
|
82,370
|
Castle Creek Pharmaceutical Holdings, Inc. 0.13%
|
6/28/21
|
14,700
|
Evozyne LLC Series A
|
4/09/21
|
132,573
|
MedAvail Holdings, Inc.
|
7/02/12
|
500,000
|
Paragon Biosciences Emalex Capital, Inc. Series C
|
2/26/21
|
1,700,005
|
ValenzaBio, Inc. Series A
|
3/25/21
|
1,999,998
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
%ownership,
end
of period
|
Fidelity Cash Central Fund 0.06%
|
2,505,192
|
132,888,261
|
126,271,802
|
2,468
|
-
|
-
|
9,121,651
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 0.07%
|
109,402,533
|
296,590,042
|
400,571,367
|
115,302
|
-
|
-
|
5,421,208
|
0.0%
|
Total
|
111,907,725
|
429,478,303
|
526,843,169
|
117,770
|
-
|
-
|
14,542,859
|